Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;60(2):235-245.
doi: 10.1007/s00592-022-01985-x. Epub 2022 Nov 2.

Prognostic nutritional index as a risk factor for diabetic kidney disease and mortality in patients with type 2 diabetes mellitus

Affiliations

Prognostic nutritional index as a risk factor for diabetic kidney disease and mortality in patients with type 2 diabetes mellitus

Junlin Zhang et al. Acta Diabetol. 2023 Feb.

Abstract

Aims: Microinflammation and malnutrition are common in individuals with type 2 diabetes mellitus (T2DM). We aimed to validate whether prognostic nutritional index (PNI) may increase the risk of diabetic kidney disease (DKD) and all-cause mortality in T2DM patients.

Methods: This retrospective cohort study was based on the National Health and Nutrition Examination Survey (NHANES) and National Death Index (NDI) 2013-2018 database. A total of 14,349 eligible subjects were included, and 2720 of them were with T2DM. PNI was assessed by the 5 × lymphocyte count (109/L) + serum albumin (g/L). The Logistic and Cox regression analyses were conducted to investigate the risk factors of DKD and mortality in T2DM patients.

Results: For 14,349 participants represented 224.7 million noninstitutionalized residents of the United State, the average PNI was 53.72 ± 0.12, and the prevalence of T2DM was 14.89%. T2DM patients had a lower level of PNI and dietary protein intake, a higher risk of mortality, kidney injury, anemia, arterial hypertension and hyperuricemia, compared with non-T2DM subjects. DKD occurred in 35.06% of diabetic participants and a higher PNI was independently related with a lower risk of DKD (OR 0.64, 95% CI 0.459-0.892, p = 0.01) in T2DM after multivariate adjustment. During a median follow-up of 46 person-months (29-66 months), a total of 233 T2DM individuals died from all causes (mortality rate = 8.17%). Subjects with T2DM who had a higher PNI showed a lower risk of all-cause mortality (HR 0.60, 95% CI 0.37-0.97, p = 0.036).

Conclusions: PNI, as a marker of immunonutrition, correlated with the incidence of DKD, and was an independent predictor for all-cause mortality in participants with T2DM. Thus, PNI may conduce to the risk stratification and timely intervention of T2DM patients.

Keywords: All-cause mortality; Diabetic kidney disease; Immunonutrition; Prognostic nutritional index; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig.1
Fig.1
The flow chart of individual inclusion and exclusion in this study
Fig.2
Fig.2
The cutoff of PNI for the prediction of DKD and mortality. a The spline curve of PNI to predict mortality in all the individuals using cox regression analysis. b The prediction of PNI for mortality in DM subjects evaluated with receiver operating characteristic (ROC) curve. c The prediction of PNI for DKD in DM subjects evaluated with receiver operating characteristic (ROC) curve. HR: hazard ratio
Fig.3
Fig.3
The prediction of PNI for DKD and mortality in DM individuals. a Kaplan–Meier curves of survival rate in DM with different PNI levels. b Kaplan–Meier curves of survival rate in DM subjects without hypoalbuminemia in the two PNI groups.c Kaplan–Meier curves of survival rate in DM subjects without anemia in the two PNI groups. d Kaplan–Meier curves of survival rate in DM subjects with anemia in the two PNI groups

References

    1. Diabetes around the world in 2021. The IDF Diabetes Atlas 10th Edition [Internet] ed: International Diabetes Federation. p. Available from https://diabetesatlas.org/.
    1. Block TJ, Batu D, Cooper ME. Recent advances in the pharmacotherapeutic management of diabetic kidney disease. Expert Opin Pharmacother. 2022;23:791–803. doi: 10.1080/14656566.2022.2054699. - DOI - PubMed
    1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–1446. doi: 10.1056/NEJMoa2024816. - DOI - PubMed
    1. Shaman AM, Bain SC, Bakris GL, et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: a pooled analysis of SUSTAIN 6 and LEADER trials. Circulation. 2021;145:575–585. doi: 10.1161/CIRCULATIONAHA.121.055459. - DOI - PMC - PubMed
    1. WHO’s Global Health Estimates (GHE) [Internet]. pp. Available from https://www.who.int/data/global-health-estimates/.

Substances